Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Bridger Management Inceases Its Stake In TrovaGene Inc. (TROV) Via Its SPO

Page 1 of 2

Roberto Mignone’s Bridger Management has acquired more shares of TrovaGene Inc. (NASDAQ:TROV). In a Form 4 filed with the Securities and Exchange Commission, Bridger Management has disclosed purchases on July 17th of 140,000 shares at a price of $8.75 per share. Subsequently, the fund currently owns an equity stake in TrovaGene of 3.29 million shares.


Bridger Management is a New York-based hedge fund launched by Roberto Mignone in July 2000. The firm is a long/short equity hedge fund and pursues fundamental, research-oriented stock selection to construct its portfolio. Prior to launching his own shop, Roberto Mignone co-founded Blue Ridge Capital with John Griffin in 1996. Even before that, he had worked at Julian Roberson’s Tiger Management, which consequently puts Mignone’s fund on the list of Tiger Cub hedge funds. When Roberto Mignone stepped down from Blue Ridge Capital to start his own firm, he was joined by the healthcare junior analyst Blake Goodner from that firm. This might partially explain Bridger Management’s high exposure to the healthcare sector, which currently accounts for 47.34% of its public equity portfolio. The hedge fund has been successful in delivering attractive returns throughout its existence, generating an annualized return of 16% net-of-fees since its inception in mid-2007. The fund recorded a loss of 20% amid the financial crisis of 2008, but managed to get back on track in the following years. As stated by its most recent 13F filing, Roberto Mignone’s Bridger Capital manages a public equity portfolio worth $1.50 billion.

Roberto Mignone
Roberto Mignone
Bridger Management

We track hedge funds and prominent investors because our research has shown that historically their stock picks delivered superior risk-adjusted returns. This is especially true in the small-cap space. The 50 most popular large-cap stocks among hedge funds had a monthly alpha of about 6 basis points per month between 1999 and 2012; however the 15 most popular small-cap stocks delivered a monthly alpha of 80 basis points during the same period. This means investors would have generated 10 percentage points of alpha per year simply by imitating hedge funds’ top 15 small-cap ideas. We have been tracking the performance of these stocks since the end of August 2012 in real time and these stocks beat the market by more than 80 percentage points (139.7% return vs. S&P 500’s less than 59% gain) over the last 34 months (see the details here).

TrovaGene Inc. (NASDAQ:TROV) is a molecular diagnostic company that is focused on developing and commercializing its proprietary diagnostic technology for the detection and monitoring of cell-free DNA in urine. To be more detailed, the technology this company is developing detects and quantitates oncogene mutations in cancer patients for better disease management. TrovaGene’s urine-based Precision Cancer MonitoringSM (PCM) platform will serve as the key growth catalyst for the company as soon as it gains adoption and is introduced among clinicians and other institutions. The company is currently engaged in 15 clinical collaborations that intend to evaluate the efficiency of this platform in detecting and monitoring different mutations related to pancreatic, colorectal, and lung cancers, as well as melanoma. It is worth mentioning that the PCM platform has already proven its superiority over tissue biopsy. In April of this year, TrovaGene revealed clinical study results that showed that the PCM platform enables detection of emerging T790M mutations in metastatic lung cancer patients with greater sensitivity than tissue biopsy. It might take quite some time until the company presents and publishes other clinical results for its studies using the PCM platform, but it is quite certain that potential positive results from new studies will surely assist the acceleration of the adoption rate for this technology.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!